LIDDS (Sweden)
Read the report The share Loading... The share Play Innovative drug delivery platform for the benefit of patients and pharma industry Watch the company presentation LIDDS' optimal drug delivery for patients and partners LIDDS is based on the proprietary drug delivery technology NanoZolid, a versatile technology that can be used to formulate most drugs and solve problems within many indication areas, offering good growth opportunities. The IP position is strong, providing coverage for both the te
Basic Information
- Category: business
- Website: http://www.liddspharma.com/
Evidence and Sources
- LIDDS (Sweden) — Official Site (official)
- LIDDS (Sweden) on linkedin (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about LIDDS (Sweden).
- Canonical profile: https://brandsource.ai/brands/lidds-sweden
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/lidds-sweden/json-ld
- Citation profile API: https://brandsource.ai/api/brands/lidds-sweden/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (78/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Read the report The share Loading... The share Play Innovative drug delivery platform for the benefit of patients and pharma industry Watch the company presentation LIDDS' optimal drug delivery for patients and partners LIDDS is based on the proprietary drug delivery technology NanoZolid, a versatile technology that can be used to formulate most drugs and solve problems within many indication areas, offering good growth opportunities. The IP position is strong, providing coverage for both the te
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.